Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben H Park

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|June 15, 2022
Circulating tumor DNA: current challenges for clinical utilityDonna K Dang, Ben H Park
Expert Review of Anticancer Therapy|August 13, 2009
Expanding role of bisphosphonates in the management of early breast cancerMichaela J Higgins, Ben H Park
American Journal of Cancer Research|August 4, 2012
Androgen receptor as a targeted therapy for breast cancerJoseph P Garay, Ben H Park
Future Oncology (London, England)|July 7, 2012
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancerJulia A Beaver, Ben H Park
British Journal of Cancer|May 27, 2021
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancerBrad A Davidson, Sarah Croessmann, Ben H Park
Advances in Experimental Medicine and Biology|March 19, 2016
Circulating Plasma Tumor DNAHeather A Parsons, Julia A Beaver, Ben H Park
Clinical Biochemistry|December 3, 2014
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicityEric S Christenson, Theodore James, Vineet Agrawal, et al.
Breast Cancer Research and Treatment|July 9, 2009
Controversial BRCA1 allelotypes in commonly used breast cancer cell linesSivasundaram Karnan, Morassa Mohseni, Yuko Konishi, et al.
Nature Protocols|November 17, 2007
A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targetingHiroyuki Konishi, Josh Lauring, Joseph P Garay, et al.
Molecular Pharmacology|April 2, 2021
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not FluorouracilEric S Christenson, Anthony Gizzi, Junru Cui, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|June 15, 2022
Circulating tumor DNA: current challenges for clinical utilityDonna K Dang, Ben H Park
Expert Review of Anticancer Therapy|August 13, 2009
Expanding role of bisphosphonates in the management of early breast cancerMichaela J Higgins, Ben H Park
American Journal of Cancer Research|August 4, 2012
Androgen receptor as a targeted therapy for breast cancerJoseph P Garay, Ben H Park
Future Oncology (London, England)|July 7, 2012
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancerJulia A Beaver, Ben H Park
British Journal of Cancer|May 27, 2021
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancerBrad A Davidson, Sarah Croessmann, Ben H Park
Advances in Experimental Medicine and Biology|March 19, 2016
Circulating Plasma Tumor DNAHeather A Parsons, Julia A Beaver, Ben H Park
Clinical Biochemistry|December 3, 2014
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicityEric S Christenson, Theodore James, Vineet Agrawal, et al.
Breast Cancer Research and Treatment|July 9, 2009
Controversial BRCA1 allelotypes in commonly used breast cancer cell linesSivasundaram Karnan, Morassa Mohseni, Yuko Konishi, et al.
Nature Protocols|November 17, 2007
A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targetingHiroyuki Konishi, Josh Lauring, Joseph P Garay, et al.
Molecular Pharmacology|April 2, 2021
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not FluorouracilEric S Christenson, Anthony Gizzi, Junru Cui, et al.
Pageof 6